Literature DB >> 9704164

The efficacy and use of anticonvulsants in mood disorders.

R T Dunn1, M S Frye, T A Kimbrell, K D Denicoff, G S Leverich, R M Post.   

Abstract

Carbamazepine and valproate have utility in the acute and prophylactic treatment of mood disorders that appears comparable with that of lithium, but there are emerging differences as well, including responsiveness in some lithium-nonresponsive illness subtypes. Carbamazepine and valproate are generally well tolerated, but each has its own adverse effect profile and proclivity for pharmacokinetic interactions. The high potency (anticonvulsant) benzodiazepines have utility in mood disorders as adjuncts to mood stabilizers and often can obviate the need for neuroleptics. Several small studies suggest that the dihydropyridine L-type calcium channel blockers can be useful mood stabilizers, and several new antiepileptic agents, especially lamotrigine and gabapentin, may have mood-stabilizing properties. The actions of electroconvulsive therapy as they relate to activation of endogenous anticonvulsant processes, and the potential therapeutic effects of nonconvulsive repeated transcranial magnetic stimulation of brain, are promising areas of mood disorder research.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704164

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  12 in total

1.  Psychiatric Uses of Newer Anticonvulsants.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

Review 2.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

3.  Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium.

Authors:  C Thomas Gualtieri; Lynda G Johnson
Journal:  MedGenMed       Date:  2006-08-23

Review 4.  Pharmacologic treatment of geriatric mania.

Authors:  William M McDonald; John Wermager
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

5.  Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study.

Authors:  A Gabriel
Journal:  Eat Weight Disord       Date:  2007-03       Impact factor: 4.652

6.  Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania.

Authors:  Michael J Reinstein; John G Sonnenberg; Thomas G Hedberg; Lynne E Jones; Polina Reyngold
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

7.  Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study.

Authors:  Katrin Druschky; Stefan Bleich; Renate Grohmann; Rolf R Engel; Alexandra Kleimann; Susanne Stübner; Waldemar Greil; Sermin Toto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-01       Impact factor: 5.270

8.  Anticonvulsant drugs in bipolar disorder.

Authors:  H Grunze; S Schlösser; B Amann; J Walden
Journal:  Dialogues Clin Neurosci       Date:  1999-06       Impact factor: 5.986

9.  Review of the use of Topiramate for treatment of psychiatric disorders.

Authors:  Danilo Arnone
Journal:  Ann Gen Psychiatry       Date:  2005-02-16       Impact factor: 3.455

10.  Psychopharmacology of topiramate: from epilepsy to bipolar disorder.

Authors:  Marco Mula; Andrea E Cavanna; Francesco Monaco
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.